Proxima Concepts group of companies
Proxima Concepts Limited is an international biopharmaceutical R&D company based in Jersey, Channel Islands, with a focus on developing proprietary drug delivery and discovery technologies to advance healthcare and therapeutics. The company has made significant advances since 2000, including the development of oral peptides, vaccine delivery vehicles, and cell function modulating therapeutics, aiming to fulfill unmet needs in the biotechnology industry.
Industries
Nr. of Employees
small (1-50)
Proxima Concepts group of companies
Products
Oral peptide delivery platform
A tablet/capsule formulation technology designed to enhance intestinal uptake of peptides and other macromolecules to achieve systemic exposure after oral dosing; demonstrated in animals and humans with typical systemic delivery in the single-digit percentage range of administered dose.
Lipidic oral vaccine delivery vehicles
Range of lipid-based vehicles (liposomes, emulsions, micelles) engineered to target intestinal immune tissue and elicit mucosal and systemic immune responses via oral administration; includes proprietary manufacturing techniques for these vehicles.
Membrane mosaic combinatorial targeting platform
A combinatorial platform that constructs membrane-based receptor probes for in vivo or whole-cell screening to identify targeting receptors and prototype delivery vehicles; used to discover molecules that modulate TNF responses for arthritis indications (preclinical stage).
Constrained oligopeptide scaffold technology
Design methodology to impose secondary and tertiary structure on short oligopeptides to create multi-epitope constructs capable of combining transport, targeting and modulatory functionalities within a single therapeutic unit.
Oral peptide delivery platform
A tablet/capsule formulation technology designed to enhance intestinal uptake of peptides and other macromolecules to achieve systemic exposure after oral dosing; demonstrated in animals and humans with typical systemic delivery in the single-digit percentage range of administered dose.
Lipidic oral vaccine delivery vehicles
Range of lipid-based vehicles (liposomes, emulsions, micelles) engineered to target intestinal immune tissue and elicit mucosal and systemic immune responses via oral administration; includes proprietary manufacturing techniques for these vehicles.
Membrane mosaic combinatorial targeting platform
A combinatorial platform that constructs membrane-based receptor probes for in vivo or whole-cell screening to identify targeting receptors and prototype delivery vehicles; used to discover molecules that modulate TNF responses for arthritis indications (preclinical stage).
Constrained oligopeptide scaffold technology
Design methodology to impose secondary and tertiary structure on short oligopeptides to create multi-epitope constructs capable of combining transport, targeting and modulatory functionalities within a single therapeutic unit.
Services
Collaborative R&D and feasibility studies
Partnered research and fully-funded feasibility projects with pharmaceutical and biotechnology organizations to test delivery vehicles and vaccine candidates.
Early-phase clinical development support
Design and conduct of Phase I and Phase IIa clinical trials for orally administered peptide formulations, including clinical protocol development and human study execution.
GMP formulation scale-up and manufacturing support
Scale-up of prototype oral peptide formulations to GMP manufacture and support for manufacturing transfer and launch in target markets.
Lipidic vaccine vehicle development
Design and prototype manufacturing of lipid-based oral vaccine vehicles intended to target intestinal immune inductive sites and generate mucosal immunity.
Collaborative R&D and feasibility studies
Partnered research and fully-funded feasibility projects with pharmaceutical and biotechnology organizations to test delivery vehicles and vaccine candidates.
Early-phase clinical development support
Design and conduct of Phase I and Phase IIa clinical trials for orally administered peptide formulations, including clinical protocol development and human study execution.
GMP formulation scale-up and manufacturing support
Scale-up of prototype oral peptide formulations to GMP manufacture and support for manufacturing transfer and launch in target markets.
Lipidic vaccine vehicle development
Design and prototype manufacturing of lipid-based oral vaccine vehicles intended to target intestinal immune inductive sites and generate mucosal immunity.
Expertise Areas
- Oral biologics delivery
- Vaccine delivery and mucosal immunology
- Peptide engineering and scaffold design
- In vivo combinatorial screening and targeting
Key Technologies
- Oral peptide delivery platforms
- Lipid-based vaccine delivery (liposomes, emulsions, micelles)
- Fluid membrane mosaic combinatorial platform
- Constrained oligopeptide scaffolds